Abstract. Elongator protein 3 (ELP3), the catalytic subunit of the elongator complex of RNA polymerase II, is involved in various functions, including transcriptional elongation, chromatin modification and cytoskeletal regulation. In this study, ELP3 expression was immunohistochemically examined in normal uterus tissue and uterine endometrioid adenocarcinoma tissue. ELP3 was abundantly expressed in both the proliferative and secretory phases of the endometrial cycle. However, ELP3 expression levels varied among cases of endometrioid adenocarcinoma. In patients with endometrioid adenocarcinoma, a low ELP3 expression was correlated to a high T-factor (p=0.036), tumor stage (p=0.001), lymph node metastasis (p<0.001), resistance to chemotherapy (p=0.045), recurrence (p=0.004) and poor prognosis (p=0.003). Univariate and multivariate analyses revealed that a low ELP3 expression was an independent factor for poor prognosis. In conclusion, this is the first study to examine the clinical implications of ELP3 expression in cancer.
Introduction
Elongator protein 3 (ELP3), the catalytic subunit of the elongator complex of RNA polymerase II, is involved in transcriptional elongation (1, 2) . Besides transcriptional elongation, ELP3 possesses various functions, including chromatin modification by acetylation of histones (2) and demethylation of paternal DNA in zygotes (3) . ELP3 is required for cell cycle progression in the presence of DNA-damaging agents in yeast (4) . However, the opposite effect was reported in humans; ELP3 overexpression causes cell cycle arrest in a human embryonic kidney cell line (5) . ELP3 also acetylates actin or tubulin in the microtubules of neurons (6) (7) (8) (9) . ELP3 mutation results in the degeneration of motor neurons in humans, suggesting a role for ELP3 in the migration and differentiation of neurons (10) . Although a number of functions of ELP3 are known, the role of ELP3 in cancers and its clinical implications have yet to be studied.
Endometrioid adenocarcinoma is the most common invasive malignancy of the female genital system (11, 12) . Despite advances in the methods of detection and treatment, the prognosis of patients with endometrioid adenocarcinoma remains unfavorable. We examined the clinical implications of the expression of a number of markers, including CDCP1 and ALDH1, in endometrioid adenocarcinoma. ELP3 expression has not been studied in endometrial tissue of the uterus. In the present study, ELP3 expression was immunohistochemically examined in normal endometrium and clinical samples with endometrioid adenocarcinoma, and its clinical implications were evaluated.
Materials and methods
Patients and methods. One hundred patients who underwent surgery for endometrioid adenocarcinoma at Osaka University Hospital, Japan, during the period between January 1998 and January 2007 were examined. Clinicopathological findings of the patients are shown in Table I . Patient ages ranged from 22 to 75 years (median 54.7). Resected specimens were macroscopically examined to determine the location and size of the tumors. Normal endometrial tissue (6 cases in the proliferative and 4 in the secretory phase), collected from patients with functional bleeding, was included as a control. Histological specimens were fixed in 10% formalin and paraffin-embedded. Paraffin-embedded specimens were stored in a dark room in the Department of Pathology of Osaka University Hospital at room temperature, sectioned at 4-µm at the time of staining, and stained with H&E and an immunoperoxidase procedure. The histological stage was determined according to the International Federation of Obstetricians and Gynecologists (FIGO) staging system (15) . The patients were followed up with laboratory examinations, including routine peripheral blood cell counts at 1-to 6-month intervals, X-ray, computed tomographic scan and pelvic examination at 6-to Immunohistochemistry for ELP3 and MIB-1. ELP3 expression was immunohistochemically examined with anti-ELP3 antibody (Sigma, St. Louis, MO, USA). The proliferative activity of cancer cells was examined with monoclonal antibody MIB-1 (Immunotech, Marseilles, France), thereby identifying the proliferation-associated antigen Ki-67. Following antigen retrieval using a Pascal pressurized heating chamber (Dako A/S, Glostrup, Denmark), the sections were incubated with anti-ELP3 and MIB-1, diluted at x250 and x100 magnification, respectively, and then treated with a ChemMate EnVision kit (Dako). DAB (Dako) was used as a chromogen. As the negative control, staining was carried out in the absence of the primary antibody. 
Results
Immunohistochemical findings. ELP3 expression was examined in normal endometrium. A strong ELP3 expression was detected in the endometrial glands of all the examined tissues (proliferative and secretory phases, Fig. 1A and B) . The expression of ELP3 was then examined in 100 samples of endometrioid adenocarcinoma tissue. Tumor cells revealed variable ELP3 expression levels. Of the 100 cases, 13% were classified as ELP3-high, 56 (56%) as ELP3-intermediate and the remaining 31 cases (31%) as ELP3-low (Figs. 1C-E) .
Double staining of ELP3 with MIB-1.
To examine the proliferation status of ELP3-expressing cells, double staining of ELP3 was carried out with MIB-1. ELP3-expressing and MIB-1-stained cells were almost mutually exclusive; most of the ELP3-expressing cells were negative for MIB-1, whereas most MIB-1-positive cells revealed no ELP3 expression (Fig. 2) .
Correlation of ELP3 expression with clinical variables.
The correlation of ELP3 expression levels (ELP3-high, ELP3-intermediate and ELP3-low) with clinicopathological characteristics was evaluated (Table II) . A low ELP3 expression was correlated with a high T-factor (p=0.036), stage (Table II) . Five-year DFS and OS rates were 86.7 and 90.6%, respectively. Tumors recurred in 21 patients. Of these, 15 patients succumbed to the disease. A statistically significant difference was found in DFS (p<0.001) and OS rates (p=0.001) among patients with ELP3-high, ELP3-intermediate and ELP3-low tumors (Fig. 3A and B) .
Univariate analysis showed that the T-factor, stage, histological grade, lymph node metastasis and ELP3 expression were significant factors for both OS and DFS (Table III) . The multivariate analysis revealed that ELP3 expression and histological grade were independent factors for OS. None of the factors were significant for DFS (Table III) .
Discussion
In the present study, the characteristics of patients, such as age and tumor stage, were similar to those in a previous study by Steiner et al, indicating that our results are commonly applicable to endometrioid adenocarcinoma worldwide (16) .
ELP3 expression was detected in non-cancerous endometrial glands of the proliferative and secretory phases. This is Although the role of ELP3 in normal endometrium remains to be elucidated, ELP3 may function as a tumor-suppressor in endometrioid adenocarcinoma, since a reduced expression of ELP3 correlated with a poor prognosis for patients. Low ELP3 expression was correlated with a high T-factor, an advanced stage, the occurrence of lymph node metastasis, resistance to chemotherapy and a high recurrence rate. Recently, Gu et al reported that ELP3 overexpression inhibits cell growth and causes cell cycle arrest in a human embryonic kidney cell line (5) . In the present study, ELP3-expressing cells stained negative with MIB-1, which is consistent with the findings of Gu et al.
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Li et al reported that ELP3 is required for S-phase progression in yeast in the presence of DNA-damaging agents, such as hydroxyurea (4) . By contrast, a high expression of ELP3 in humans was reported to correlate with vulnerability to anticancer drugs. This may be attributable to the difference in species. ELP3 is known to regulate the structure of chromatin and the methylation of genomes (2, 17) . Although target genes epigenetically regulated by ELP3 have not yet been reported, the identification of target genes of ELP3 may aid in understanding the various effects ELP3 has on the human and yeast cell cycle.
In conclusion, a low ELP3 expression is a poor prognostic factor in endometrioid adenocarcinoma. Further studies are required to clarify whether ELP3 expression would be a useful prognostic marker in other types of cancer.
A B Table III . Univariate and multivariate analyses of prognostic factors for overall survival (OS) and disease-free survival (DFS). -------------------------------------------------------------------------- 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

